---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-088061"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2026-08-12T12:04:06+00:00"
generated_at: "2026-08-12T12:05:06.258762+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Unicycive Q2 net loss narrows to $1.7M; FDA assigns OLC facility inspection

## Summary
- Q2 2026 net loss $1.7M ($0.06/sh) vs $6.5M loss ($0.52/sh) in Q2 2025.
- Cash, equivalents, and marketable securities $61.4M at June 30, 2026; runway into 2027.
- FDA assigned facility inspection to third-party OLC manufacturer; NDA resubmission expected after successful inspection.
- June 2026 CRL cited same manufacturing deficiencies as prior CRL; no efficacy or safety concerns.
- R&D expense $2.8M (vs $1.8M); G&A $7.4M (vs $5.2M) year-over-year.

## SEC filing metadata
- accession: 0001213900-26-088061
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2026-08-12T12:04:06+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390026088061/0001213900-26-088061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390026088061/ea0301699-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-088061
- JSON: https://secwatch.observer/filing/0001213900-26-088061.json
- Plain text: https://secwatch.observer/filing/0001213900-26-088061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.